Loading clinical trials...
Loading clinical trials...
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19
Conditions
Interventions
PF-07321332
Placebo for PF-07321332
+2 more
Locations
170
United States
Cahaba Research Inc
Pelham, Alabama, United States
The Institute for Liver Health dba Arizona Clinical Trials
Tucson, Arizona, United States
Ascada Health PC
Fullerton, California, United States
Optimus Medical Group
San Francisco, California, United States
Synergy Healthcare
Bradenton, Florida, United States
MOORE Clinical Research, Inc.
Brandon, Florida, United States
Start Date
September 9, 2021
Primary Completion Date
April 12, 2022
Completion Date
April 12, 2022
Last Updated
May 6, 2023
NCT04565665
NCT07221162
NCT06082518
NCT06631287
NCT06679140
NCT06417762
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions